Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
Silk Road Medical Trading Down 0.5 %
SILK opened at $48.14 on Friday. Silk Road Medical has a fifty-two week low of $27.21 and a fifty-two week high of $67.49. The company has a quick ratio of 3.73, a current ratio of 6.92 and a debt-to-equity ratio of 1.23. The company has a fifty day moving average of $40.36 and a two-hundred day moving average of $37.21.
Analysts Set New Price Targets
Several brokerages recently issued reports on SILK. Stifel Nicolaus reduced their target price on shares of Silk Road Medical from $55.00 to $46.00 in a report on Monday, July 18th. Citigroup cut shares of Silk Road Medical from a "neutral" rating to a "sell" rating and set a $33.00 price objective for the company. in a report on Monday, July 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, Silk Road Medical currently has an average rating of "Hold" and a consensus target price of $49.33.
Insider Transactions at Silk Road Medical
In other news, CFO Lucas W. Buchanan sold 25,000 shares of the business's stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $47.79, for a total transaction of $1,194,750.00. Following the completion of the sale, the chief financial officer now owns 191,764 shares of the company's stock, valued at $9,164,401.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Lucas W. Buchanan sold 25,000 shares of the business's stock in a transaction dated Friday, August 12th. The shares were sold at an average price of $47.79, for a total transaction of $1,194,750.00. Following the completion of the sale, the chief financial officer now owns 191,764 shares of the company's stock, valued at $9,164,401.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elizabeth H. Weatherman sold 5,000 shares of the business's stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $41.91, for a total transaction of $209,550.00. Following the sale, the director now directly owns 229,454 shares of the company's stock, valued at approximately $9,616,417.14. The disclosure for this sale can be found here. Insiders sold 95,000 shares of company stock valued at $4,212,350 over the last 90 days. Corporate insiders own 7.66% of the company's stock.